Learn more about Hexima’s technology.
Hexima is conducting a phase I/IIa clinical trial of its lead antifungal molecule, HXP124, as a treatment for fungal nail infections.
Please be advised that Hexima Limited (Company) will be holding an Extraordinary General Meeting (EGM) at 11:00am (AEST) on Monday, 5 October 2020 via an audio webcast. Registration will commence at 10:30am. Please see meeting materials below. Meeting materials (pdf)...
Dear Shareholder, I am writing to you to provide an update on Hexima’s development program. Hexima’s lead product (HXP124) is a topical treatment for nail fungus (onychomycosis). HXP124 is an easy to apply solution that is simply painted onto nails, not requiring any...
Shares in Hexima Limited are not traded on the ASX. The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2020, was at the price of $0.08 per share. Download a copy of this announcement (pdf)
Hexima Limited has released its Interim Financial Report for the six months ended 31 December 2019. View Interim Financial Report (pdf)
Presentations and Results from the 2019 Hexima Limited Annual General Meeting held 19 November 2019. AGM 2019 Chairman’s Address AGM 2019 CEO Presentation AGM 2019 Meeting Results